<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962101</url>
  </required_header>
  <id_info>
    <org_study_id>263-102-00004</org_study_id>
    <nct_id>NCT03962101</nct_id>
  </id_info>
  <brief_title>Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake</brief_title>
  <official_title>A Multicenter, Open-label, Uncontrolled Clinical Trial to Confirm the Tolerability of OPC-61815 in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the tolerability of intravenous administration of OPC-61815 at 8 or 16 mg once
      daily for a maximum of 5 days to CHF patients with volume overload despite having received
      diuretics (injection) other than vasopressin antagonists and who have difficulty with or are
      incapable of oral intake.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events(AEs)</measure>
    <time_frame>Screening period to Follow-up period, up to 16 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body weight</measure>
    <time_frame>Baseline and 5 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Make the shift table how lower limb edema is improved from Baseline, to 2, 3, 4, 5 days after dosing.</measure>
    <time_frame>Baseline and 2, 3, 4, 5 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Make the shift table how pulmonary congestion is improved from Baseline, to 2, 3, 4, 5 days after dosing.</measure>
    <time_frame>Baseline and 2, 3, 4, 5 days after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>OPC-61815 injection 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of OPC-61815 at 8 mg once daily for a maximum of 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-61815 injection 16 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of OPC-61815 at 16 mg once daily for a maximum of 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-61815 injection 8 mg</intervention_name>
    <description>once daily for a maximum of 5 days</description>
    <arm_group_label>OPC-61815 injection 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-61815 injection 16 mg</intervention_name>
    <description>once daily for a maximum of 5 days</description>
    <arm_group_label>OPC-61815 injection 16 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving loop diuretic injection at a dose equivalent to furosemide 20
             mg/day or higher

          -  CHF patients in whom lower limb edema, pulmonary congestion, and/or jugular venous
             distension due to volume overload is present

          -  Patients who are judged by the investigator or subinvestigator to have difficulty or
             be incapable of oral intake, including patients who are judged by the investigator or
             subinvestigator to require nothing by mouth(NPO) management

          -  Patients who are currently hospitalized or who are capable of being hospitalized from
             the time of informed consent until the end of the treatment period

          -  Patients who are capable of giving informed consent

        Exclusion Criteria:

          -  Patients who are on a ventricular assist device

          -  Patients who have difficulty with spontaneous respiration or who have been on tracheal
             intubation under sedative therapy

          -  Patients with severe disturbed consciousness (ie, coma or stupor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Gifu Prefectural General Medical Center</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

